On the other hand, given that we found UK-5099 to enhance the protein expression of CD200 in bulge eHFSCs, hormetic ISR stimulation may be useful in preventing immune privilege collapse in this disorder (bulge immune privilege is supported by CD200 expression, which is decreased in scarring alopecia [13, 71, 72]) Lastly, as ISR activation blocks proliferation, pharmacologically activating the ISR could be protective against chemotherapy-induced damage in the hair follicle via cell cycle-dependent mechanisms [10, 73]. Here, CD200 is linked to alopecia.